The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female participants with normal liver function. The side effects and tolerability of Imlunestrant will also be evaluated.
Participants must have a diagnosis of impaired liver function
All Participants: Female participants must be not of childbearing potential and are infertile due to surgical sterilization like hysterectomy,tubal ligation etc. or postmenopausal
All Participants: Participants must have a body mass index(BMI) between 18.0 and 42.0 kilograms per meter squared (kg/m2) at screening
Healthy Participants: Healthy females as determined by medical history, physical examination, and other screening procedures, with normal liver function
Participants must not have any known allergies to imlunestrant or related compounds
Participants must not have a history of alcoholism or drug/chemical abuse within 2 years prior to screening
Participants must not have received blood products within 2 months prior to screening
Participants must not smoke more than ten cigarettes per day or use the equivalent amount of tobacco, smoking cessation products or e-cigarettes (nicotine and non-nicotine)
Participants must not have a history of or a diagnosis of heart, kidney, respiratory or gastrointestinal disease which can alert the absorption, metabolism, or elimination of drugs
A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.